Integrative Treatment Benefits Revealed for Hyperparathyroidism

Find effective strategies in integrative treatment for hyperparathyroidism that support a comprehensive health plan.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I present a first-person, deeply integrative, and clinically practical journey through hypercalcemia and hyperparathyroidism, with a special focus on primary hyperparathyroidism. Drawing on modern, evidence-based research from leading investigators and my own clinical observations, I explain the physiology of calcium, vitamin D, and parathyroid hormone (PTH); the stepwise diagnostic workup; and decision-making between surgery and medical management. I detail why each test and therapy is used, the reasoning behind protocols, and how integrative chiropractic care fits into medically directed multidisciplinary treatment plans.

A central pillar of our model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas is medical oversight by Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine (NPI #1164426749; Texas MD License #J2933), our Medical Director and Collaborative Physician with more than 40 years of experience as an internist. Our setup reflects common integrative and injury care structures where an MD provides medical direction alongside a chiropractor. Together, we integrate chiropractic care, internal medicine, functional medicine, personal injury care, rehabilitation, and lifestyle therapeutics to create personalized, safe, and effective care pathways.

This post includes:

• Foundational physiology and the coupled dynamics of calcium, vitamin D, and PTH
• Symptom thresholds, clinical signals, and red flags in hypercalcemia
• Evidence-based testing frameworks and imaging for localization
• Clear distinctions among primary, secondary, and tertiary hyperparathyroidism
• Surgical indications, intraoperative PTH monitoring, outcomes, and postoperative care
• Medical management strategies including cinacalcet and antiresorptives
• Integrative chiropractic roles in posture, pain modulation, and fall-risk reduction
• Functional medicine tools for nutrition, gut health, sleep, stress, and environmental factors
• Case narratives illustrating diverse presentations and clinical reasoning
• Long-term monitoring, relapse prevention, and lifestyle strategies

I also share practical algorithms, quality-of-life insights, perioperative optimization, and real-world decision-making, aligning with contemporary guidelines and peer-reviewed literature. References are cited in APA-7 style and hyperlinked for easy access.

About Our Integrative Team and Care Model: Internal Medicine Oversight, Chiropractic Integration, and Functional Rehabilitation

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, and I serve patients within a multidisciplinary framework designed for complex endocrine and musculoskeletal conditions.

• Medical Oversight and Direction

• • Maria Guadalupe Cardenas, MD, is Board Certified in Internal Medicine (NPI #1164426749; Texas MD License #J2933) and serves as Medical Director and Collaborative Physician at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic), El Paso, Texas. With over 40 years of experience, Dr. Cardenas leads medical decision-making for hypercalcemia and hyperparathyroidism, ensuring diagnostic accuracy, coordinated specialty referrals, safe pharmacotherapy, and perioperative management. Her oversight is foundational to patient safety and quality of care.

• Chiropractic and Functional Medicine Integration

• • My role integrates chiropractic medicine and functional medicine into a medically directed plan. I focus on musculoskeletal integrity, pain modulation, functional biomechanics, and lifestyle optimization. Calcium, vitamin D, and PTH are not abstract lab values; they directly affect bone architecture, posture, gait, joint loading, and pain. By dovetailing biomechanical rehabilitation with metabolic correction, we improve functional outcomes and reduce fragility risks.

• Clinic Infrastructure

• • Our clinic is a multidisciplinary setup common in integrative and injury care. An MD provides medical direction alongside chiropractic clinicians, supported by physical therapy, nutrition, health coaching, behavioral insights, and targeted diagnostics. This structure enables evidence-based, patient-centered, and safety-first care under internal medicine oversight.

• Interdisciplinary Coordination

• • We coordinate through structured care pathways, shared clinical dashboards, risk stratification, quality metrics, and cohesive follow-up schedules. Case reviews align metabolic and musculoskeletal care plans around consensus guidelines for primary hyperparathyroidism. We monitor outcomes, adjust strategies, and communicate clearly to patients and families.

Clinical Observations from Practice: Early Signals, Musculoskeletal Overlap, and Postural Dynamics

From my clinical work at HealthCoach Clinic and Injury Medical Clinic PA, several patterns have emerged:

• Subtle Early Signs

• • Patients with mild hypercalcemia often present with fatigue, irritability, sleep disruption, and cognitive fog. These nonspecific complaints are frequently misattributed to stress or aging. Recognizing this constellation in the context of elevated calcium is crucial for early intervention.

• Musculoskeletal Overlap

• • Chronic PTH elevation drives bone resorption and demineralization, contributing to axial low back pain, proximal muscle weakness, and myofascial strain. I routinely see patients whose musculoskeletal pain is magnified by skeletal fragility and altered load distribution.

• Posture and Gait

• • Postural compensations such as thoracic kyphosis, lumbar hyperlordosis, and anterior pelvic tilt often reflect evolving changes in skeletal architecture. Gait alterations are common, driven by discomfort, microfracture risk, and cortical bone thinning.

• Nutrition Pitfalls

• • High supplemental calcium intake or overuse of calcium carbonate (e.g., multiple daily antacids) can exacerbate hypercalcemia. Without medical guidance, patients may inadvertently trigger milk-alkali syndrome, especially if coexisting granulomatous disease or malignancy is present.

• Functional Medicine Lens

• • Gut health, vitamin D absorption, magnesium status, sleep quality, and metabolic stress are modifiable contributors. Addressing these factors alongside medical and surgical management improves outcomes. My observations underscore the importance of a systems approach.

References:

• HealthCoach Clinic. Clinical observations and integrative care models. healthcoach.clinic/
• Jimenez, A. LinkedIn professional profile. www.linkedin.com/in/dralexjimenez/

Why Calcium, Vitamin D, and PTH Move Together: A Physiological Deep Dive

Understanding the physiology is the foundation of precise diagnosis and targeted therapy. Here is how calcium, vitamin D, and parathyroid hormone (PTH) interact.

• Calcium

• • Key roles: Cardiac conduction, neuronal excitability, muscle contraction, vascular tone, enzymatic activation, and coagulation depend on tightly regulated extracellular calcium levels.
  • Binding and Albumin: Total serum calcium is partially bound to albumin. Low albumin can cause pseudohypocalcemia. To avoid misinterpretation, clinicians use a corrected calcium formula or measure ionized calcium, the physiologically active fraction.

• Vitamin D

• • Sources and Conversion: Vitamin D arises from skin synthesis via UVB exposure and dietary intake. The liver converts it to 25-hydroxyvitamin D [25(OH)D], the storage marker we measure. The kidney converts 25(OH)D to 1,25-dihydroxyvitamin D [calcitriol], the active hormone.
  • Forms: Vitamin D3 (cholecalciferol) often has higher potency and receptor affinity than Vitamin D2 (ergocalciferol). Prescription ergocalciferol 50,000 IU weekly is standard in deficiency protocols under medical oversight (Tripkovic et al., 2012).

• Parathyroid Hormone (PTH)
  • Secreted by parathyroid glands, PTH raises serum calcium by:

• • • Enhancing bone resorption via osteoblast-mediated signaling to osteoclasts
    • Increasing renal calcium reabsorption
    • Stimulating renal 1-alpha hydroxylase to produce calcitriol, boosting intestinal calcium absorption

• • PTH also promotes renal phosphate excretion, balancing mineral metabolism.
• Coupled Physiology

• • When serum calcium drops, PTH rises, orchestrating bone, kidney, and gut responses to restore levels. In primary hyperparathyroidism (PHPT), autonomous PTH secretion, usually from a parathyroid adenoma, drives hypercalcemia and perturbs neuromuscular and skeletal integrity (Bilezikian et al., 2014; Bilezikian et al., 2018).

References:

• Bilezikian, J. P., et al. (2014). Primary hyperparathyroidism: Evaluation and management. Journal of Clinical Endocrinology & Metabolism, 99(10), 3561–3569.
• Bilezikian, J. P., et al. (2018). Primary hyperparathyroidism. New England Journal of Medicine.
• Tripkovic, L., et al. (2012). Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status. European Journal of Clinical Nutrition, 66(12), 1283–1288.

Recognizing Hypercalcemia: Symptom Thresholds, Clinical Signals, and When to Act

Hypercalcemia ranges from silent to life-threatening. Knowing thresholds and patterns prevents delays and complications.

• Asymptomatic or Subtle Early Signs

• • Mildly elevated calcium (e.g., 5–11 mg/dL) often causes few or no symptoms. Patients may experience fatigue, thirst, mood changes, or muscle aches. These complaints warrant careful correlation with labs.

• Classic Triad

• • Polyuria, polydipsia, and nocturia reflect impaired renal concentrating ability due to calcium’s effect on the kidney.

• Gastrointestinal and Neurocognitive

• • Nausea, constipation, abdominal pain, anorexia, and confusion intensify as calcium surpasses 11–12 mg/dL.

• Severe Manifestations

• • Obtundation, acute kidney injury (AKI) from dehydration, altered mental status, and potential cardiac arrhythmias typically occur at higher calcium levels (>13–14 mg/dL). Immediate intervention is required (Goltzman, 2016).

• Bone and Renal Complications

• • Osteopenia/osteoporosis, fragility fractures, and nephrolithiasis are hallmark long-term complications of sustained PTH-driven hypercalcemia (Silverberg et al., 2006; Coe et al., 2016).

References:

• Goltzman, D. (2016). Evaluation and management of hypercalcemia. JAMA.
• Silverberg, S. J., et al. (2006). Skeletal disease in primary hyperparathyroidism. Journal of Clinical Endocrinology & Metabolism.
• Coe, F. L., et al. (2016). Kidney stone disease. New England Journal of Medicine.

Evidence-Based Diagnostic Framework: How I Structure the Workup

Accurate diagnosis demands careful sequencing and interpretation. Here is my stepwise approach under Dr. Cardenas’s medical oversight.

• Initial Laboratory Evaluation

• • Total serum calcium and albumin; consider corrected calcium or ionized calcium for precise assessment.
  • Intact PTH (iPTH) to determine if hypercalcemia is PTH-mediated.
  • 25(OH)D to evaluate deficiency or excess; correct deficiency cautiously to avoid exacerbating hypercalcemia.
  • Creatinine and eGFR for renal function; phosphate levels for mineral balance.
  • Urinalysis and 24-hour urinary calcium to assess hypercalciuria, stone risk, and help distinguish PHPT from FHH.

• Interpretation Basics

• • High calcium + high/inappropriately normal PTH suggests primary hyperparathyroidism.
  • High calcium + suppressed PTH points toward malignancy-associated hypercalcemia, vitamin D intoxication, or granulomatous disease (e.g., sarcoidosis).
  • Low/normal calcium + high PTH calls for evaluation of secondary hyperparathyroidism (vitamin D deficiency, CKD).

• Radiological Tests

• • DEXA for bone mineral density and fracture risk stratification.
  • Neck ultrasound for parathyroid gland visualization.
  • Sestamibi scan and/or 4D-CT for localization of adenomas before surgery.
  • Renal ultrasound/CT to evaluate stones.

• Special Considerations

• • Ionized calcium is the most physiologically relevant measure and correlates strongly with parathyroid adenoma size, sometimes outperforming total calcium in predictive capacity.
  • Albumin correction reduces misclassification; when feasible, prioritize ionized calcium.

References:

• Bilezikian, J. P., et al. (2014). Primary hyperparathyroidism: Evaluation and management. Journal of Clinical Endocrinology & Metabolism.
• Lezaic, L., et al. (2014). 99mTc-sestamibi scintigraphy in primary hyperparathyroidism: An evidence-based review. European Journal of Nuclear Medicine and Molecular Imaging.

Distinguishing Primary, Secondary, and Tertiary Hyperparathyroidism: Clinical and Pathophysiologic Clarity

Not all elevated PTH is the same. Distinguishing forms of hyperparathyroidism guides treatment choices.

• Primary Hyperparathyroidism (PHPT)

• • Etiology: Most commonly a solitary parathyroid adenoma; less commonly multiglandular hyperplasia or carcinoma.
  • Biochemistry: Elevated or inappropriately normal PTH in the face of elevated calcium.
  • Clinical Impact: Skeletal demineralization, nephrolithiasis, neurocognitive changes.

• Secondary Hyperparathyroidism

• • Etiology: Physiologic PTH increase in response to hypocalcemic stimuli such as vitamin D deficiency or chronic kidney disease (CKD).
  • Biochemistry: Low/normal calcium with high PTH; phosphate often elevated in CKD.
  • Clinical Impact: High bone turnover; requires correcting the underlying cause (vitamin D repletion, CKD management).

• Tertiary Hyperparathyroidism

• • Etiology: Long-standing secondary HPT results in autonomously functioning parathyroid hyperplasia.
  • Biochemistry: Elevated PTH with elevated calcium persisting even after correction of the original stimulus (e.g., post-renal transplant).
  • Clinical Impact: Often requires surgical intervention; complicated CKD-related mineral disorders (Block et al., 2010).

References:

• Block, G. A., et al. (2010). Chronic kidney disease and secondary/tertiary hyperparathyroidism. Journal of the American Society of Nephrology.
• Bilezikian, J. P., et al. (2018). Primary hyperparathyroidism. New England Journal of Medicine.

Modern Presentations of Hyperparathyroidism: Beyond Bones, Stones, and Groans

Historically, PHPT was defined by bones, stones, and groans:

• Bones: Osteitis fibrosa cystica, subperiosteal resorption, fractures
• Stones: Nephrolithiasis
• Groans: GI and neurocognitive complaints

Today, widespread biochemical screening identifies many patients who are asymptomatic or minimally symptomatic. A subset presents with normocalcemic primary hyperparathyroidism, characterized by elevated PTH with normal adjusted total and ionized calcium, after excluding secondary causes (Bilezikian et al., 2014; Bilezikian et al., 2018).

References:

• Bilezikian, J. P., et al. (2014). Primary hyperparathyroidism: Evaluation and management. Journal of Clinical Endocrinology & Metabolism.
• Bilezikian, J. P., et al. (2018). Primary hyperparathyroidism. New England Journal of Medicine.

Medications and Conditions That Elevate Calcium or PTH: Practical Review

Medication reconciliation is indispensable under internal medicine oversight.

• Thiazide Diuretics

• • Reduce urinary calcium excretion and can increase serum calcium. Temporarily suspending and rechecking labs can clarify contributions (Goltzman, 2016).

• Lithium

• • Alters calcium-sensing receptor (CaSR) set-point, reducing parathyroid sensitivity to calcium. Coordination with psychiatry is essential (Brown et al., 2005).

• Immobilization

• • Elevated bone resorption due to disuse increases calcium. Rehabilitation and progressive mechanical loading reduce resorption signals.

• Hyperthyroidism

• • Accelerates bone turnover; treating thyroid excess reduces calcium release.

• Granulomatous Disease

• • Sarcoidosis and TB can increase extrarenal calcitriol production and raise calcium. Managing the underlying condition and modulating vitamin D intake are critical (Adams & Hewison, 2003).

• Milk-Alkali Syndrome

• • Excess calcium carbonate intake drives hypercalcemia, metabolic alkalosis, and renal dysfunction; ask quantitatively about antacid use (Medarov, 2014).

References:

• Goltzman, D. (2016). Evaluation and management of hypercalcemia. JAMA.
• Brown, E. M., et al. (2005). Calcium-sensing receptor physiology. American Journal of Physiology-Renal Physiology.
• Adams, J. S., & Hewison, M. (2003). Vitamin D, hypercalcemia, and granulomatous disease. Endocrine Reviews.
• Medarov, B. I., et al. (2014). Milk-alkali syndrome revisited. Annals of Clinical Biochemistry.

Normocalcemic Primary Hyperparathyroidism: Criteria and Clinical Meaning

Diagnosing normocalcemic PHPT requires precision:

• Normal adjusted total calcium and normal ionized calcium
• Elevated PTH measured at least twice over 3–6 months
• Exclusion of secondary causes:

• • Vitamin D deficiency (25[OH]D < 30 ng/mL)
  • Renal insufficiency (eGFR < 60 mL/min/1.73 m²)
  • Medications (lithium, thiazides)
  • Malabsorption and other metabolic bone diseases

Why it matters:

• Avoid mislabeling compensatory physiology as primary disease
• Prevent unnecessary surgery
• Target reversible contributors (vitamin D repletion, CKD management)

References:

• Bilezikian, J. P., et al. (2014). Primary hyperparathyroidism: Evaluation and management. Journal of Clinical Endocrinology & Metabolism.

Clinical Features Raising Suspicion for Primary Hyperparathyroidism

Several features prompt closer evaluation:

• Marked Hypercalcemia

• • Persistent elevated calcium with inappropriately normal or elevated PTH

• Osteitis Fibrosa Cystica

• • Rare today; look for subperiosteal resorption and cystic lesions on imaging.

• Fragility Fractures

• • Vertebral compression, hip, or wrist fractures signal skeletal involvement

• Renal Complications

• • Nephrolithiasis, nephrocalcinosis, reduced eGFR

• Proximal Myopathy

• • Shoulder and hip girdle weakness; difficulty rising from a chair or climbing stairs

• 24-hour Urine Findings

• • Hypercalciuria supports PHPT and stone risk assessment; low urine calcium suggests FHH.

References:

• Silverberg, S. J., et al. (2006). Skeletal disease in primary hyperparathyroidism. Journal of Clinical Endocrinology & Metabolism.

Laboratory Evaluation: The Tests I Order and Why

When I suspect PHPT, I order:

• Comprehensive Metabolic Panel (CMP)

• • Serum calcium and albumin for corrected calcium
  • Renal function (BUN, creatinine, eGFR)

• Intact Parathyroid Hormone (PTH)

• • Confirms inappropriate elevation in the setting of elevated calcium

• Serum 25-Hydroxyvitamin D

• • Guides safe repletion strategies

• Serum Phosphorus

• • PTH-driven changes in phosphate handling are diagnostic clues

• 24-hour Urine Calcium and Creatinine

• • Differentiates PHPT (normal/high urine calcium) from FHH (low urine calcium)
  • Quantifies stone risk

Optional tests:

• • Ionized calcium when albumin variability or acid-base disturbances may distort totals
  • Urine citrate for stone risk
  • Serum magnesium for bone and PTH regulation
  • PTHrP in malignancy contexts

References:

• Pollak, M. R., et al. (1995). Familial hypocalciuric hypercalcemia and CaSR mutations. New England Journal of Medicine.

Imaging Evaluation: Skeletal and Renal Impact, Surgical Localization

Imaging clarifies disease burden and guides surgical planning.

• DEXA Bone Mineral Density

• • Spine, hip, and distal radius (cortical site)
  • If available, vertebral fracture assessment (VFA) and trabecular bone score (TBS) add microarchitectural insight (Martineau et al., 2014)

• Renal Ultrasound

• • Detects stones and nephrocalcinosis; informs hydration and nephrology intervention

• Neck Ultrasound and Sestamibi Scan

• • Not required for diagnosis; valuable for localization before surgery. 4D-CT is useful in reoperative cases or equivocal findings (Lezaic et al., 2014)

References:

• Lezaic, L., et al. (2014). 99mTc-sestamibi scintigraphy in primary hyperparathyroidism. European Journal of Nuclear Medicine and Molecular Imaging.
• Martineau, P., et al. (2014). Trabecular bone score and fracture risk. Osteoporosis International.

Indications for Parathyroid Surgery: Criteria I Use to Guide Referral

Surgery is the only curative therapy for PHPT. I counsel patients using established criteria:

• Age less than 50 years
• Serum calcium greater than 1.0 mg/dL above the upper limit of normal
• Kidney stones (history or imaging evidence)
• Reduced renal function

• • eGFR < 60 mL/min/1.73 m² or documented decline in kidney function

• Osteoporosis

• • DEXA T-score greater than 2.5 at any site or history of fragility fracture

• 24-hour urine calcium

• • >250 mg/day in women or >350 mg/day in men

Even if criteria are not met, a surgical consult is appropriate for confirmed PHPT to consider patient preference and surgeon expertise (Bilezikian et al., 2014; Bilezikian et al., 2018).

References:

• Bilezikian, J. P., et al. (2014). Primary hyperparathyroidism: Evaluation and management. Journal of Clinical Endocrinology & Metabolism.
• Bilezikian, J. P., et al. (2018). Primary hyperparathyroidism. New England Journal of Medicine.

“Cracking the Low Thyroid Code: A Comprehensive Assessment Guide”- Video

Surgical Pathway and Perioperative Optimization: What We Do Before, During, and After

Under Dr. Cardenas’s medical direction, perioperative care prioritizes safety and precision.

• Preoperative Preparation

• • Hydration and electrolyte optimization
  • Review medications affecting calcium (thiazides, lithium)
  • Localization imaging to plan focused parathyroidectomy, minimizing exploration

• Intraoperative Strategy

• • Intraoperative PTH monitoring confirms successful gland removal. A drop of >50% from baseline within 10–15 minutes indicates biochemical cure.

• Postoperative Care

• • Monitor for hypocalcemia and hungry bone syndrome, where bone avidly absorbs calcium after removal of PTH excess.
  • Calcium and vitamin D supplementation under medical supervision to prevent symptomatic hypocalcemia (Wong et al., 2015)

• Rehabilitation and Chiropractic Recovery Pathways

• • Gradual return-to-activity focusing on balance, core stability, and posture.
  • Gentle manual therapy and mobilization to reduce nociceptive input and improve alignment without compromising bone integrity

References:

• Wong, P., et al. (2015). Hungry bone syndrome: Pathophysiology and management. Journal of Clinical Endocrinology & Metabolism.

Surgical Outcomes and Pathology: Setting Realistic Expectations

Understanding surgical outcomes reduces anxiety and supports informed consent.

• Typical Pathology

• • Single adenoma: ~80–90%
  • Multigland disease: ~6–15%
  • Parathyroid carcinoma: Rare (~0.5–1%)

• Cure Rates

• • Biochemical cure approaches ~98% in experienced hands

• Benefits of Surgery

• • Normalization of calcium, PTH, and urinary calcium
  • Neurocognitive improvements: Energy, mood, executive function often improve
  • Reduced kidney stone risk
  • Improved bone mineral density, especially at cortical sites

• Balanced View

• • Cardiovascular outcomes and mortality may not consistently change after parathyroidectomy; we focus on bones, kidneys, and quality of life (Bilezikian et al., 2018).

References:

• Bilezikian, J. P., et al. (2018). Primary hyperparathyroidism. New England Journal of Medicine.
• Silverberg, S. J., et al. (2003). Bone mineral density changes after parathyroidectomy. Journal of Clinical Endocrinology & Metabolism.

Medical Management When Surgery is Deferred or Not Indicated: How We Stabilize Physiology

For patients who defer surgery or do not meet criteria, our goals are to reduce serum calcium, improve bone density, minimize renal complications, and support function.

• Monitoring

• • Twice-yearly labs: calcium, PTH, 25(OH)D, eGFR
  • DEXA every 1–2 years with VFA/TBS if available

• Vitamin D Optimization

• • Aim for> 20 ng/mL; many guidelines favor> 30 ng/mL depending on fracture risk
  • Repletion must be cautious to avoid worsening hypercalcemia (Tripkovic et al., 2012)

• Antiresorptives

• • Bisphosphonates (e.g., alendronate) to increase BMD and reduce fracture risk.

• Calcimimetics

• • Cinacalcet lowers PTH and serum calcium by sensitizing CaSR on parathyroid cells.
  • Typical initiation at 30 mg twice daily; titrate based on calcium response
  • Monitor for QT concerns and GI side effects; personalize therapy (Peacock et al., 2005)

• Hydration and Diet

• • Maintain adequate fluid intake
  • Moderate calcium intake unless medically indicated
  • Avoid excessive vitamin D supplementation without guidance

References:

• Peacock, M., et al. (2005). Cinacalcet hydrochloride for the treatment of primary hyperparathyroidism. New England Journal of Medicine.
• Tripkovic, L., et al. (2012). Comparison of vitamin D2 and vitamin D3 supplementation. European Journal of Clinical Nutrition.

Functional Medicine Framework: Nutrition, Gut Health, Sleep, Stress, and Environmental Factors

Functional medicine complements medical management by addressing systemic modulators of calcium homeostasis and bone health.

• Nutrition

• • Emphasize anti-inflammatory dietary patterns, adequate protein for bone matrix, magnesium and vitamin K2 to support mineralization.
  • Tailor calcium intake to avoid extremes that provoke PTH changes

• Gut Health

• • Evaluate malabsorption, microbiome imbalances, and GI inflammation impacting vitamin D and calcium absorption.

• Sleep and Stress

• • Optimize sleep architecture; stress modulation to improve endocrine balance and adherence.

• Movement and Load

• • Safe mechanical loading to stimulate osteogenesis; avoid high-impact activities in advanced bone fragility

• Environmental and Medication Review

• • Identify exposures and drugs influencing calcium homeostasis (thiazides, lithium)

References:

• Institute for Functional Medicine. (n.d.). Functional medicine approaches to bone health.

Role of Integrative Chiropractic Care: Biomechanical Stabilization, Pain Modulation, and Rehabilitation

Chiropractic care within medically directed pathways improves function while protecting bone integrity.

• Biomechanical Stabilization

• • Targeted interventions normalize spinal mechanics, reduce myofascial strain, and improve posture, countering skeletal changes from chronic hypercalcemia.

• Pain Modulation

• • Gentle, evidence-informed manual techniques reduce nociception, improve proprioception, and facilitate neuromuscular re-education.

• Rehabilitation

• • Strength and stability programs minimize fracture risk, emphasize low-impact, controlled loading, and support bone health via mechanotransduction.

• Safety-First Protocols

• • Under Dr. Cardenas’s oversight, avoid high-velocity thrusts in severe osteoporosis or fracture history; prioritize mobilization, soft tissue techniques, and postural training.

• Outcome Tracking

• • Use functional measures, patient-reported outcomes, and bone density trends to adjust care coherently with medical treatment and nutrition.

Vitamin D: Practical Nuances, Supplementation Strategies, and Safety

Vitamin D management requires precision in hyperparathyroidism contexts.

• Assessment and Correction

• • Measure 25(OH)D; replete carefully to reduce PTH without provoking hypercalcemia.

• Form Choice

• • D3 (cholecalciferol) demonstrates stronger potency vs D2 (ergocalciferol); prescription D2 50,000 IU weekly is standard in deficiency treatment (Tripkovic et al., 2012)

• Dietary Sources

• • D3: cod liver oil, oily fish, fortified foods, multivitamins, standalone supplements
  • D2: sun-dried mushrooms, some fortified foods; prescription ergocalciferol

• Calcitriol

• • The active hormone reserved for renal or specific metabolic indications under medical supervision; boosts intestinal absorption and reduces renal calcium loss

References:

• Tripkovic, L., et al. (2012). Comparison of vitamin D2 and vitamin D3 supplementation. European Journal of Clinical Nutrition.

Laboratory Precision: Ionized Calcium vs. Total Calcium and Albumin Correction

Technical choices matter.

• Ionized Calcium

• • Reflects free, physiologically active calcium; valuable when albumin variability or acid-base shifts distort total calcium. Correlates strongly with adenoma size and surgical outcomes.

• Total Calcium and Albumin

• • Corrected calcium or ionized calcium prevents pseudohypocalcemia due to hypoalbuminemia. Prioritize accurate interpretation to avoid mismanagement.

Imaging and Localization: Building a Surgical Map

Localization optimizes surgical efficiency and reduces complications.

• Neck Ultrasound

• • Noninvasive and bedside-friendly; identifies enlarged parathyroid glands but is operator-dependent

• Sestamibi Scan

• • Nuclear medicine study leveraging mitochondrial uptake differences; common for adenoma localization (Lezaic et al., 2014)

• 4D-CT

• • High-resolution anatomical and perfusion imaging; valuable in reoperative cases or equivocal findings

• Bone Density

• • DEXA for T-scores guiding fracture risk and tracking treatment efficacy

References:

• Lezaic, L., et al. (2014). 99mTc-sestamibi scintigraphy in primary hyperparathyroidism. European Journal of Nuclear Medicine and Molecular Imaging.

Practical Algorithm: From Lab to Plan

My typical algorithm under medical oversight:

• Elevated calcium? Repeat test
• Confirm persistent hypercalcemia: Order PTH, 25(OH)D, phosphorus, CMP/albumin, eGFR, 24-hour urine calcium
• Consider ionized calcium if acid-base issues or albumin variability
• Review medications (thiazides, lithium); quantify OTC calcium (e.g., antacid use)
• Exclude secondary causes (vitamin D deficiency, CKD, malabsorption)
• If PHPT confirmed? Imaging:

• • DEXA (spine/hip/distal radius), VFA/TBS if available, renal ultrasound, neck imaging for localization

• Assess surgical criteria? Refer to experienced endocrine surgeon if met or patient prefers
• If not surgical? Manage medically:

• • Monitor labs twice yearly; optimize vitamin D; consider cinacalcet; treat osteoporosis; hydrate; exercise and rehab; chiropractic stabilization

• Track outcomes? Adjust plan with Dr. Cardenas’s oversight

Integrative Care in El Paso: Internal Medicine + Chiropractic + Functional Medicine

Our coordinated model at Mission Plaza Injury Medical Clinic ensures comprehensive, safe, and patient-centered care.

• Medical Oversight (Dr. Cardenas, MD)

• • Confirms diagnosis, manages safety
  • Addresses medication interactions (e.g., lithium, thiazides)
  • Triages surgical referrals and coordinates imaging
  • Monitors renal function and systemic implications

• Integrative Chiropractic (Dr. Jimenez, DC, APRN, FNP-BC)

• • Assesses musculoskeletal impact of hypercalcemia/PHPT
  • Designs spine and extremity stabilization programs
  • Implements fall prevention strategies
  • Coordinates with rehab for strength and balance

• Functional Medicine and Rehabilitation

• • Nutrition, bone-building lifestyle, and comorbidity management
  • Monitors bone density and fracture risk
  • Evidence-based physical therapy modalities integrated with care plans

A Patient-Centered Journey: Understanding Hypercalcemia and Clinical Decision-Making

When I encounter a patient with elevated calcium, especially values greater than 12 mg/dL, my priorities are confirming the finding, evaluating urgency, and building a differential diagnosis that extends beyond hyperparathyroidism (Goltzman, 2016; Stewart, 2005).

• Key Differential Diagnoses

• • Primary hyperparathyroidism
  • Hypercalcemia of malignancy: PTHrP-mediated mechanisms, osteolytic metastases, or increased calcitriol in some lymphomas (Stewart, 2005; Rosner et al., 2004)
  • Vitamin D toxicity
  • Vitamin A toxicity
  • Milk-alkali syndrome from high calcium carbonate intake
  • Thiazide diuretic use
  • Lithium therapy
  • Immobilization
  • Hyperthyroidism
  • Granulomatous disease (sarcoidosis, TB)
  • Lymphoma
  • TPN influences
  • Adrenal insufficiency

Clinical pearls:

• • Recheck calcium promptly
  • Quantify supplement intake (“How many Tums per day?”)
  • Ionized calcium is most informative when acid-base status is abnormal; corrected total calcium may suffice otherwise.

References:

• Stewart, A. F. (2005). Hypercalcemia associated with cancer. Journal of Clinical Oncology.
• Rosner, I. A., et al. (2004). Hypercalcemia of malignancy. Journal of Clinical Oncology.

The Tale of Two Cities: How Screening and Vitamin D Status Shape Disease

Presentation varies globally based on screening practices and nutritional status (Silverberg et al., 2000; Zhu et al., 2018).

• United States Profile

• • Routine calcium screening uncovers mild, asymptomatic cases
  • Average calcium ~4 mg/dL, PTH ~118 pg/mL
  • Average vitamin D ~21 ng/mL
  • Osteitis fibrosa cystica rare; DEXA reveals osteopenia/osteoporosis
  • Kidney stones reduced from historic ~60% to 15–20%

• Beijing, China Profile

• • Less routine screening; severe symptomatic presentations
  • Average calcium ~0 mg/dL
  • PTH often >20× ULN
  • Vitamin D severely low (~8 ng/mL)
  • Osteitis fibrosa cystica in 60%, pathologic fractures in 35%, stones in 42%

Vitamin D deficiency fuels PTH excess: low gut calcium absorption stimulates PTH, and existing adenomas secrete more hormone, amplifying disease burden.

References:

• Silverberg, S. J., et al. (2000). Presentation of asymptomatic primary hyperparathyroidism: Proceedings of the third international workshop. Journal of Clinical Endocrinology & Metabolism.
• Zhu, Y., et al. (2018). Primary hyperparathyroidism in a Chinese population: A single-center experience. Endocrine Practice.

Case Narratives: Real-World Clinical Reasoning, Outcomes, and Lessons

I often find that the best way to teach is to share clinical stories that illustrate nuanced decision-making, therapeutic choices, and the interplay between biochemistry and function.

Case 1: An Asymptomatic Cardiac Patient with Surgical Cure and Immediate Well-Being

• Patient: 68-year-old male with non-obstructive CAD, non-ischemic cardiomyopathy, chronic systolic heart failure, atrial fibrillation
• Labs:

• • PTH 190 pg/mL
  • Calcium 8 mg/dL
  • GFR 4 mL/min/1.73m²
  • PTH 158 pg/mL on repeat
  • Vitamin D 3 ng/mL
  • 24-hour urine calcium 364 mg/24h (elevated for men)

• Imaging:

• • DEXA: Near normal
  • Neck ultrasound: Solid nodule posterior to left thyroid lobe (12 × 20 × 11 mm) suggestive of parathyroid adenoma

• Surgical Course:
  • Sestamibi confirmation
  • Intraoperative PTH:

• • • Baseline 533 pg/mL
    • Post-visualization 314 pg/mL
    • 5 min post-excision 69 pg/mL
    • 10 min 49 pg/mL
    • 15 min 42 pg/mL

• • Pathology: Hypercellular parathyroid adenoma
• Outcome:

• • Immediate improvement in energy and stamina post-op
  • Post-op labs: Calcium 4 mg/dL, PTH 131 pg/mL, Vitamin D 19 ng/mL

• Interpretation:

• • Elevated postoperative PTH likely due to vitamin D insufficiency and temporary set-point changes; monitor and optimize vitamin D toward 30–40 ng/mL

• Lesson:

• • Symptoms previously attributed to heart failure overlapped with hypercalcemia; surgical correction improved quality of life unexpectedly

Case 2: An Elderly Patient with Hypercalcemic Crisis and Complex Medical Management

• Patient: 85-year-old female with dementia
• ER Presentation: Calcium 15.8 mg/dL, weakness, confusion
• Acute Management: IV fluids, calcitonin, zoledronic acid
• Malignancy Workup: PET/CT negative; benign lesions; hyperparathyroidism confirmed
• Family Decision: Surgery declined due to age and comorbidities
• Outpatient Course:

• • October 2024: Calcium 3 mg/dL, PTH 201 pg/mL, Vitamin D 32.2 ng/mL, 24-hour urine calcium 100 mg
  • December: Calcium rises to 4 mg/dL, PTH 147 pg/mL
  • January 2025: Calcium 8 mg/dL, initiate cinacalcet 30 mg daily
  • Rehospitalization with calcium 8 mg/dL; additional zoledronic acid
  • Titrate cinacalcet up to 90 mg twice daily; calcium stabilizes only with intermittent infusions; slight renal decline complicates scheduling

• Lessons:

• • Medical management demands frequent labs and flexible, rapid adjustments
  • Hydration is pivotal to prevent crises; caregiver education is essential
  • Cinacalcet may be insufficient alone; periodic bisphosphonates can stabilize calcium

Case 3: A Pilot with Chronic Foot Pain and Postoperative Resolution

• Patient: 57-year-old male, pilot, chronic bilateral foot pain
• Labs:

• • Calcium 5 mg/dL; repeat 11.1 mg/dL
  • PTH 107 pg/mL; repeat 84 pg/mL
  • GFR 5 mL/min/1.73m²
  • Vitamin D 2 ng/mL
  • 24-hour urine calcium 184 mg/24h (normal)

• Imaging:

• • DEXA: Excellent BMD (spine T-score +2.1)
  • Neck ultrasound: TI-RADS 4 thyroid nodule (benign biopsy); adenoma not visualized
  • Renal ultrasound: Non-obstructing kidney stone (left)

• Decision:

• • Kidney stone is an absolute indication for surgery; proceed with parathyroidectomy

• Outcome:

• • Significant improvement in chronic foot pain immediately post-op
  • Post-op labs: Calcium 7 mg/dL, PTH 32 pg/mL, GFR 70 mL/min/1.73m², Vitamin D 39 ng/mL

• Interpretation:

• • Hyperparathyroidism can manifest as chronic musculoskeletal pain syndromes beyond classic bone pain; surgical cure can relieve such symptoms

• Lesson:

• • Think broadly: endocrine disorders can drive persistent pain presentations; ruling in PHPT may avert unnecessary orthopedic procedures.

Physiologic Deep Dive: Why Hypercalcemia Feels the Way It Does

Patients ask why fatigue, muscle weakness, or cognitive fog appear with high calcium. The mechanistic answers guide therapy.

• Neuromuscular Excitability

• • Elevated extracellular calcium reduces sodium channel permeability and diminishes neuronal excitability, producing muscle weakness and lethargy.

• Gastrointestinal Function

• • Smooth muscle tone and enteric neuronal signaling change, leading to constipation and abdominal discomfort.

• Renal Handling

• • Hypercalcemia induces natriuresis and diuresis, causing polyuria and volume depletion, which can further raise calcium—a vicious cycle broken by hydration.

• Cardiac Conduction

• • Calcium can shorten the QT interval and affect contractility and rhythm at high levels.

• Bone Remodeling

• • PTH increases RANKL expression on osteoblasts, promoting osteoclast differentiation, raising resorption and calcium release. Antiresorptives counter this process.

References:

• Goltzman, D. (2016). Evaluation and management of hypercalcemia. JAMA.

Distinguishing Familial Hypocalciuric Hypercalcemia (FHH) from PHPT: Avoiding Unnecessary Surgery

FHH can mimic PHPT but requires different management.

• FHH Hallmarks

• • Mild lifelong hypercalcemia
  • Normal/mildly elevated PTH
  • Low urine calcium (<200 mg/24h)
  • Calcium/creatinine clearance ratio <0.01
  • CaSR mutations (Pollak et al., 1995)

• PHPT Hallmarks

• • Elevated serum calcium with inappropriately high PTH
  • Normal/high urine calcium
  • Often adult onset; no lifelong pattern

If testing aligns with FHH, pursue genetics and avoid parathyroidectomy.

References:

• Pollak, M. R., et al. (1995). Familial hypocalciuric hypercalcemia and CaSR mutations. New England Journal of Medicine.

Kidney Stones and Nephrocalcinosis: Protecting Renal Health

Hypercalciuria and urinary supersaturation raise stone risk. Our renal strategies include:

• Hydration

• • Urine volume goals often >2–2.5 liters/day

• Dietary Moderation

• • Adequate food-based calcium to bind oxalate in the gut
  • Limit excess sodium to reduce urinary calcium
  • Encourage citrate intake (citrus fruits) to reduce stone formation

• Monitoring

• • 24-hour urine for calcium, oxalate, citrate, sodium
  • Renal ultrasound for stones and nephrocalcinosis

• Surgical Correction

• • Parathyroidectomy reduces stone risk by normalizing calcium and PTH (Coe et al., 2016)

References:

• Coe, F. L., et al. (2016). Kidney stone disease. New England Journal of Medicine.

Bone Health Optimization: Translating Biochemistry into Structure and Safety

We combine medical therapies with targeted rehabilitation and chiropractic care:

• Antiresorptives

• • Bisphosphonates increase BMD; evidence supports fracture risk reduction in PHPT managed non-surgically (Black et al., 1998)

• Mechanical Loading

• • Progressive resistance training stimulates osteogenesis via mechanotransduction (Wnt signaling), strengthening cortical bone.

• Fall Prevention

• • Balance and proprioception training reduce fracture risk; home safety assessments.

• Nutritional Cofactors

• • Magnesium supports PTH secretion and vitamin D metabolism
  • Vitamin K2 aids osteocalcin carboxylation for matrix mineralization
  • Protein ensures collagen scaffold strength

References:

• Black, D. M., et al. (1998). Bisphosphonates in osteoporosis. New England Journal of Medicine.

Patient Education: Simple Steps with Big Impact

We emphasize clear, actionable advice:

• Hydration routines: Morning, midday, and afternoon check-ins
• Regular physical activity: Guided programs matching capacity and goals
• Avoid excessive OTC calcium; discuss supplementation
• Maintain balanced dietary calcium rather than elimination
• Share complete medication lists; mention thiazides and lithium
• Report muscle weakness, constipation, thirst, or confusion promptly

Surgical Expertise and Localization: Why the Right Surgeon Matters

Selecting an experienced endocrine surgeon improves success and reduces complications:

• Multimodal localization (ultrasound, sestamibi, 4D-CT)
• Intraoperative PTH monitoring
• Protocols for multigland disease
• Structured follow-up to confirm cure and monitor recovery

Postoperative Care and Functional Recovery: Coordinating Rehabilitation and Chiropractic Care

After successful parathyroidectomy:

• Biochemical normalization

• • Confirm calcium and PTH trends post-op

• Symptom relief

• • Many patients report improved energy, mood, and muscle function

• Rehabilitation

• • Advance strength and balance programs when labs stabilize

• Monitoring BMD

• • DEXA at 12–24 months to track gains; VFA/TBS for microarchitecture

Chiropractic care and physical therapy focus on safe progression and long-term resilience.

Hyperparathyroidism and Quality of Life: Evidence from Long-Term Follow-Up

Asymptomatic patients often ask if they will feel better after surgery. A 10-year RCT (SIPH trial) provides nuance:

• Pretorius et al. (2020) studied 191 patients randomized to parathyroidectomy vs observation
• Findings:

• • Surgery achieves biochemical cure
  • Quality of life improvements on SF-36 were limited primarily to vitality
  • Both groups reported similar CPRS improvements over time

• Clinical Conclusion:

• • In asymptomatic PHPT, surgery may not consistently alter overall QoL compared to observation over 10 years.
  • Observation does not necessarily worsen QoL.

This informs shared decision-making, emphasizing safety, patient goals, and individual risk profiles.

References:

• Pretorius, M., et al. (2020). Effects of parathyroidectomy on quality of life in asymptomatic primary hyperparathyroidism: A 10-year follow-up of a prospective, randomized controlled trial (SIPH-trial). Journal of Bone and Mineral Research.

Functional Medicine Touchpoints: Root Causes and Systemic Modifiers

We explore and address contributors impacting calcium regulation and bone health:

• Vitamin D Synthesis and Activation

• • Sun exposure, hepatic/renal function, granulomatous disease

• Inflammation

• • Chronic inflammation affects bone remodeling; anti-inflammatory nutrition strategies deployed.

• Gut Health

• • Evaluate celiac disease, IBD, and microbial imbalances; correct malabsorption that drives secondary HPT.

• Endocrine Crosstalk

• • Thyroid, adrenal, and sex hormones influence bone turnover; coordinate endocrine evaluations.

References:

• Institute for Functional Medicine. (n.d.). Functional medicine approaches to bone health.

Minimizing Risks in Cinacalcet Therapy: Practical Safety Considerations

Cinacalcet is effective but requires monitoring:

• Start low, titrate based on calcium levels
• Monitor QT interval risks in susceptible individuals
• In pregnancy, weigh risks and benefits; involve obstetrics
• Monitor for GI side effects; support diet to enhance tolerance
• Coordinate with antiresorptives if osteoporosis is present

References:

• Peacock, M., et al. (2005). Cinacalcet hydrochloride for the treatment of primary hyperparathyroidism. New England Journal of Medicine.

Counseling on Hydration and Activity: Behavioral Tools That Work

We use simple, effective behavior strategies:

• Hydration routines with reminders
• Walking and resistance exercise tailored to fall risk
• Educate on signs of dehydration and hypercalcemia exacerbation (polyuria, thirst, fatigue)
• Home safety assessments: reduce fall hazards, improve lighting, use assistive devices

Tracking Outcomes: What We Measure and Why

Objective data guide care adjustments and demonstrate progress:

• Serum calcium and PTH
• 25(OH)D
• eGFR
• DEXA, VFA, TBS
• 24-hour urine calcium
• Functional metrics: Timed Up-and-Go, grip strength, hip abductor strength, balance tests

Integrative Chiropractic and Bone Safety: Technique Considerations

In osteopenic/osteoporotic patients:

• Prefer low-force, high-specificity manual techniques
• Emphasize instrument-assisted adjustments and gentle mobilizations
• Prioritize exercise-based stabilization over high-velocity maneuvers in high-risk segments
• Integrate breathing and core engagement for daily spine protection

Preventing Misdiagnosis: The Value of Rechecking and Context

Avoid errors by:

• Rechecking calcium to rule out transient elevations
• Quantifying antacid/calcium intake
• Recognizing acid-base context for ionized calcium interpretation

Patient Autonomy and Shared Decision-Making: Respecting Preferences

We encourage consultations with experienced surgeons even when criteria are borderline. Patients should feel informed, empowered, and supported in choosing observation or surgery aligned with their values and risk profile.

How Our Team Integrates Care: Step-by-Step Workflow

• Initial Evaluation

• • Comprehensive history, physical examination, and initial labs (calcium, albumin, ionized calcium when appropriate, PTH, 25(OH)D, creatinine/eGFR, phosphate)

• Medical Direction

• • Cardenas oversees diagnostics, risk stratification, safety, imaging selection, medication management, and surgical referral.s

• Chiropractic and Rehabilitation

• • Functional assessments; gentle mobilization; myofascial work; stability programs tailored to bone health

• Functional Medicine

• • Nutrition mapping; micronutrient support; sleep and stress protocols; gut interventions

• Shared Decision-Making

• • Patient education on risks and benefits of surgery vs medical management; personalized plans aligned with life goals

• Follow-Up

• • Coordinated appointments; data tracking; responsive care adjustments; prevention focus

Personal Injury Context: Special Considerations for Hyperparathyroidism

• Risk of Fragility

• • Bone demineralization increases injury susceptibility and complicates rehabilitation.

• Collaborative Care

• • Coordinate imaging for fracture detection; adapt manual therapy to avoid high-risk maneuvers; fall-prevention strategies.

• Return to Function

• • Progressive rehab focusing on safe range-of-motion, gait retraining, and ergonomic adjustments

Advanced Topics: Malignancy, Granulomatous Disease, and Non-PTH Hypercalcemia

• Malignancy-Related Hypercalcemia

• • Often presents with suppressed PTH; consider PTHrP-mediated hypercalcemia; urgent oncology coordination; use hydration, bisphosphonates, calcitonin as indicated (Stewart, 2005; Rosner et al., 2004)

• Granulomatous Disorders

• • Sarcoidosis and similar conditions can increase extrarenal calcitriol production; manage underlying disease and modulate vitamin D intake carefully (Adams & Hewison, 2003)

References:

• Stewart, A. F. (2005). Hypercalcemia associated with cancer. Journal of Clinical Oncology.
• Adams, J. S., & Hewison, M. (2003). Vitamin D, hypercalcemia, and granulomatous disease. Endocrine Reviews.

Long-Term Follow-Up and Prevention Strategies: Sustaining Health

• Monitoring Cadence

• • Define intervals for labs and DEXA; adjust based on clinical course and interventions.

• Lifestyle Foundations

• • Nutrition, hydration, movement, sleep, and stress strategies; review supplements regularly

• Relapse Prevention

• • Surveillance for recurrent hyperparathyroidism; multigland disease monitoring

Education on Dietary Calcium: Why Food-First Makes Sense

Patients often ask whether to eliminate dietary calcium. We advise:

• Do not eliminate food-based calcium entirely

• • Very low intake can increase PTH and worsen bone loss

• Aim for balanced intake

• • Around 1,200 mg/day from dietary sources for many adults (personalized to age, sex, and risk)

• Coordinate with vitamin D

• • Appropriate levels support absorption and bone health; avoid excessive supplementation without lab guidance

Special Populations: Younger Patients and Genetic Syndromes

In patients under 30 years or with multigland disease:

• MEN1: Parathyroid hyperplasia, pancreatic neuroendocrine tumors, pituitary adenomas
• MEN2: RET mutations; medullary thyroid carcinoma; parathyroid involvement possible
• Familial isolated hyperparathyroidism

Coordinate with genetics and endocrinology for testing and family counseling (Bilezikian et al., 2018).

References:

• Bilezikian, J. P., et al. (2018). Primary hyperparathyroidism. New England Journal of Medicine.

Addressing Immobilization and Hyperthyroidism: Integrating Rehabilitation and Endocrinology

• Immobilization

• • Increased bone resorption elevates calcium; activity and graded loading counterbalance catabolic signals.

• Hyperthyroidism

• • Treat thyroid excess to reduce bone turnover; integrate bone protection strategies during endocrine therapy

Quality of Care: Internal Medicine + Chiropractic Collaboration

Our multidisciplinary model ensures:

• Medical rigor via internal medicine oversight
• Chiropractic precision for musculoskeletal stabilization
• Functional medicine personalization
• Rehabilitative safety and performance tracking

This alignment is common in integrative and injury care clinics, where an MD directs alongside a DC, as in our El Paso practice.

Summary: Our Integrated Approach to Hypercalcemia and Primary Hyperparathyroidism

• Hypercalcemia has multiple causes; we evaluate systematically
• PHPT remains a leading cause; surgery is curative with high success
• Medical and lifestyle management can stabilize calcium and protect bone when surgery is deferred
• Integrative chiropractic care supports neuromuscular recovery and fall prevention
• Internal medicine oversight ensures accurate diagnosis, safety, and coordinated specialty care
• Functional medicine addresses systemic influences on calcium and bone health
• Patient education and shared decision-making empower choices

Professional References and Evidence Base

• Bilezikian, J. P., et al. (2014). Primary hyperparathyroidism: Evaluation and management. Journal of Clinical Endocrinology & Metabolism, 99(10), 3561–3569.
• Bilezikian, J. P., et al. (2018). Primary hyperparathyroidism. New England Journal of Medicine.
• Tripkovic, L., et al. (2012). Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status. European Journal of Clinical Nutrition, 66(12), 1283–1288.
• Stewart, A. F. (2005). Hypercalcemia associated with cancer. Journal of Clinical Oncology, 23(36), 849–860.
• Silverberg, S. J., et al. (2006). Skeletal disease in primary hyperparathyroidism. Journal of Clinical Endocrinology & Metabolism, 91(10), 4002–4009.
• Lezaic, L., et al. (2014). 99mTc-sestamibi scintigraphy in primary hyperparathyroidism: An evidence-based review. European Journal of Nuclear Medicine and Molecular Imaging, 41(11), 2037–2055.
• Wong, P., et al. (2015). Hungry bone syndrome: Pathophysiology and management. Journal of Clinical Endocrinology & Metabolism, 100(10), 3627–3633.
• Peacock, M., et al. (2005). Cinacalcet hydrochloride for the treatment of primary hyperparathyroidism. New England Journal of Medicine, 353(20), 2336–2347.
• Institute for Functional Medicine. (n.d.). Functional medicine approaches to bone health.
• Coe, F. L., et al. (2016). Kidney stone disease. New England Journal of Medicine, 375(10), 964–973.
• Martineau, P., et al. (2014). Trabecular bone score and fracture risk. Osteoporosis International, 25(11), 2469–2475.
• Pollak, M. R., et al. (1995). Familial hypocalciuric hypercalcemia and CaSR mutations. New England Journal of Medicine, 333(21), 1436–1440.
• Goltzman, D. (2016). Evaluation and management of hypercalcemia. JAMA.
• Adams, J. S., & Hewison, M. (2003). Vitamin D, hypercalcemia, and granulomatous disease. Endocrine Reviews.
• Black, D. M., et al. (1998). Bisphosphonates in osteoporosis. New England Journal of Medicine.
• Medarov, B. I., et al. (2014). Milk-alkali syndrome revisited. Annals of Clinical Biochemistry.
• Silverberg, S. J., et al. (2003). Bone mineral density changes after parathyroidectomy. Journal of Clinical Endocrinology & Metabolism.
• Rosner, I. A., et al. (2004). Hypercalcemia of malignancy. Journal of Clinical Oncology.
• Pretorius, M., et al. (2020). Effects of parathyroidectomy on quality of life in asymptomatic primary hyperparathyroidism: A 10-year follow-up of a prospective, randomized controlled trial (SIPH-trial). Journal of Bone and Mineral Research.
• Silverberg, S. J., et al. (2000). Presentation of asymptomatic primary hyperparathyroidism: Proceedings of the third international workshop. Journal of Clinical Endocrinology & Metabolism.
• Zhu, Y., et al. (2018). Primary hyperparathyroidism in a Chinese population: A single-center experience. Endocrine Practice.
• Brown, E. M., et al. (2005). Calcium-sensing receptor physiology. American Journal of Physiology-Renal Physiology.

SEO tags: hyperparathyroidism, primary hyperparathyroidism, hypercalcemia, calcium, parathyroid hormone, PTH, vitamin D, ionized calcium, pseudohypocalcemia, parathyroid adenoma, parathyroidectomy, sestamibi scan, 4D-CT, DEXA, osteoporosis, nephrolithiasis, cinacalcet, bisphosphonates, hungry bone syndrome, integrative chiropractic, functional medicine, internal medicine oversight, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, El Paso Texas, Dr Maria Guadalupe Cardenas MD, Dr Alex Jimenez DC APRN FNP-BC CFMP IFMCP ATN CCST, HealthCoach Clinic, personalized medicine, multidisciplinary care, quality of life, endocrine surgery, rehabilitation, bone health, kidney stones, mechanotransduction, RANKL, trabecular bone score, fall prevention, hydration, diet, magnesium, vitamin K2, lithium, thiazides, granulomatous disease, sarcoidosis, malignancy-associated hypercalcemia, PTHrP